AcelRx Pharmaceuticals, Inc. (ACRX) Q2 2021 Results Conference Call August 16, 2021 4:30 PM ET Company Participants Vincent Angotti – Chief Executive Officer Raffi Asadorian – Chief Financial Officer Pamela P. Palmer – Chief Medical Officer Conference Call Participants Brandon Folkes – Cantor Fitzgerald Ed Arce – H.C. Wainwright & Co Michael J. Higgins – Ladenburg Thalmann Operator Welcome to the AcelRx Second Quarter 2021 Earnings Call. This call is being webcast live on the events page of the Investors se ...

FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number: 001-35068 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ACELRX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 41-2193603 (State or other jurisdiction ...

AcelRx Pharmaceuticals, Inc. (ACRX) Q1 2021 Earnings Conference Call May 17, 2021 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vince Angotti - Chief Executive Officer Pam Palmer - Chief Medical Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Michael Higgins - Ladenburg Thalmann Ed Arce - H.C. Wainwright Operator Welcome to the AcelRx First Quarter 2021 Earnings Call. This call is being webcast live on the events page of the Investors section of AcelRx's w ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number: 001-35068 ACELRX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 41-2193603 (State or other jurisdictio ...

AcelRx Pharmaceuticals, Inc. (ACRX) Q4 2020 Earnings Conference Call March 15, 2021 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Pam Palmer - Chief Medical Officer Steve Yun - Physician Expert in Oral & Dental Anesthesiology Conference Call Participants Brandon Folkes - Cantor Fitzgerald Evan Seigerman - Credit Suisse Edward Marks - Ladenburg Thalmann Ed Arce - H.C. Wainwright Operator Welcome to the AcelRx's Fourth Quarter and Full-Year 2020 Conference Call. This call is being ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35068 ACELRX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 41-2193603 (State or other jurisdiction of inc ...

AcelRx Pharmaceuticals, Inc. (ACRX) Q3 2020 Earnings Conference Call November 5, 2020 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - Chief Executive Officer & Director Pamela Palmer - Co-Founder, Chief Medical Officer & Director Conference Call Participants Michael Higgins - Ladenburg Evan Seigerman - Credit Suisse Operator Welcome to the AcelRx Third Quarter 2020 Conference Call. This call is being webcast live on the Events page of the Investors section of Acel ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number: 001-35068 ACELRX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 41-2193603 (State or other jurisdi ...

AcelRx Pharmaceuticals, Inc. (ACRX) Q2 2020 Earnings Conference Call August 10, 2020 4:30 PM ET Company Participants Raffi Asadorian - CFO Vincent Angotti - CEO & Director Pamela Palmer - Co-Founder, Chief Medical Officer & Director Conference Call Participants Brandon Folkes - Cantor Fitzgerald & Co. Michael Higgins - Ladenburg Thalmann & Co. Evan Seigerman - Crédit Suisse Operator Welcome to the Acelrx Second Quarter 2020 Conference Call. This call is being webcast live on the Events page of the Investors ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number: 001-35068 ACELRX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 41-2193603 (State or other jurisdiction ...